NASDAQ:NXTC

Nextcure Stock Insider Trading

etoro logo Buy NXTC
*Your capital is at risk
$3.15
-0.250 (-7.35%)
At Close: Jun 03, 2026

NextCure Stock Insider Power

Based on the 100 latest insides trades, we have calculated the insider power to be positive at 100.00. In total, the insiders bought 6.76M and sold 0 NXTC shares in the last 100 trades. The insider score can be negative despite buy/sell ratio being positive. The score focuses on the quality of the trades.

Insider Power

(Last 100 transactions)
100.00
Buy 6.76M shares
Sell 0 shares
100% Buy Activity
Negligible or No Correlation

No Significant Signals

No statistically significant buy or sell signals detected in recent insider data.

Historical Insider Trades

Date Type Person Role Amount
Jan 30, 2026
Buy
Employee Stock Option (Right to Buy)
A-Award
Cobourn Steven P.
Chief Financial Officer
C-Suite Officer 14 670
Value: $159.2K
Jan 30, 2026
Buy
Employee Stock Option (Right to Buy)
A-Award
Richman Michael
President & CEO
CEO / President 38 190
Value: $414.4K
Jan 30, 2026
Buy
Employee Stock Option (Right to Buy)
A-Award
Shaw Kevin G.
Sr Vp, General Counsel
Officer 8 270
Value: $89.7K
Jan 30, 2026
Buy
Employee Stock Option (Right to Buy)
A-Award
Guha Udayan
Chief Medical Officer
Officer 14 670
Value: $159.2K
Jan 30, 2026
Buy
Employee Stock Option (Right to Buy)
A-Award
Kundu Sourav
Sr Vp, Dev. & Mfg.
Officer 8 270
Value: $89.7K
Jan 30, 2026
Buy
Employee Stock Option (Right to Buy)
A-Award
Mayer Timothy
Chief Operating Officer
C-Suite Officer 14 670
Value: $159.2K
Jun 20, 2025
Buy
Common Stock
Simcere Zaiming, Inc.
10 Percent Owner
10% Owner 0
Value: $0
Jun 20, 2025
Buy
Common Stock
Simcere Zaiming, Inc.
10 Percent Owner
10% Owner 0
Value: $0
Jun 20, 2025
Buy
Stock Option (Right to Buy)
A-Award
Houston John G
Director
Director 18 700
Value: $9K
Jun 20, 2025
Buy
Stock Option (Right to Buy)
A-Award
Jones Elaine V
Director
Director 18 700
Value: $9K
Jun 20, 2025
Buy
Stock Option (Right to Buy)
A-Award
Kabakoff David S
Director
Director 28 050
Value: $13.2K
Jun 20, 2025
Buy
Stock Option (Right to Buy)
A-Award
Borgman Anne Elizabeth
Director
Director 18 700
Value: $9K
Jun 20, 2025
Buy
Stock Option (Right to Buy)
A-Award
Webster Stephen W
Director
Director 18 700
Value: $9K
Jun 20, 2025
Buy
Stock Option (Right to Buy)
A-Award
Feigal Ellen
Director
Director 18 700
Value: $9K
Jun 20, 2025
Buy
Stock Option (Right to Buy)
A-Award
Feigal Ellen
Director
Director 18 700
Value: $9K
Jun 20, 2025
Buy
Stock Option (Right to Buy)
A-Award
Webster Stephen W
Director
Director 18 700
Value: $9K
Jun 20, 2025
Buy
Stock Option (Right to Buy)
A-Award
Borgman Anne Elizabeth
Director
Director 18 700
Value: $9K
Jun 20, 2025
Buy
Stock Option (Right to Buy)
A-Award
Kabakoff David S
Director
Director 28 050
Value: $13.2K
Jun 20, 2025
Buy
Stock Option (Right to Buy)
A-Award
Houston John G
Director
Director 18 700
Value: $9K
Jun 20, 2025
Buy
Stock Option (Right to Buy)
A-Award
Jones Elaine V
Director
Director 18 700
Value: $9K
Feb 01, 2025
Buy
Employee Stock Option (Right to Buy)
Guha Udayan
Chief Medical Officer
Officer 65 000
Value: $98.2K
Feb 01, 2025
Buy
Employee Stock Option (Right to Buy)
Guha Udayan
Chief Medical Officer
Officer 66 125
Value: $80.7K
Feb 01, 2025
Buy
Employee Stock Option (Right to Buy)
Guha Udayan
Chief Medical Officer
Officer 52 900
Value: $118.0K
Feb 01, 2025
Buy
Employee Stock Option (Right to Buy)
Guha Udayan
Chief Medical Officer
Officer 117 375
Value: $94.5K
Feb 01, 2025
Buy
Employee Stock Option (Right to Buy)
Guha Udayan
Chief Medical Officer
Officer 117 375
Value: $94.5K

About Insider Power

Insider Power is a proprietary algorithm developed by StockInvest.us to evaluate the significance of insider transactions. The calculation considers the size, type, and timing of transactions, as well as the insider’s role within the company.

It is important to note that, in general, there is little to no correlation between insider transactions and short-term stock price movements. In one of our studies, only 0.22%* of stocks with insider activity showed a measurable correlation — and even then, it was unclear whether the effect was caused by insider actions or simply by the stock’s broader trend.

While our algorithms are designed to highlight potentially meaningful signals, these cannot be regarded as statistically significant on their own. Insider trading activity should therefore be seen as informative rather than as direct trading guidance. The Insider Power metric was created to present this information in a clearer and more accessible way, helping investors better understand the possible context of insider activity.

* October 6th, 2025 - Tested on 5562 stocks

Click to get the best stock tips daily for free!
ABOUT NEXTCURE INC.
NextCure
NextCure, Inc., a clinical-stage biopharmaceutical company, engages in discovering and developing novel immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. Its lead product candidate is NC318, which is in Phase II clinical trials for the treatment of advanced or metastatic solid tumors. The company is also developing NC410, which is in Phase I for novel immunomedicine designed to block immune sup...
GOLDEN STAR
Ticker Change Signal Date
LITE
$905.00
3.65% Jun 01
RUN
$12.83
15.74% May 06
GLBE
$31.61
0.569% May 05
SAP
$172.39
4.80% May 05
ADBE
$243.57
5.20% Apr 29

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE